Two Sigma Investments’s Summit Therapeutics SMMT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$38.2M Buy
2,259,925
+1,563,211
+224% +$23.4M 0.03% 672
2026
Q2
$10.2M Sell
696,714
-284,471
-29% -$5.04M 0.01% 1510
2026
Q1
$18.6M Buy
981,185
+402,937
+70% +$6.52M 0.02% 991
2025
Q4
$10.1M Buy
578,248
+553,218
+2,210% +$10.4M 0.01% 1116
2025
Q3
$517K Buy
+25,030
New +$607K ﹤0.01% 2965
2024
Q2
– Sell
-23,579
Closed -$97.6K – 3301
2024
Q1
$97.6K Sell
23,579
-82,600
-78% -$328K ﹤0.01% 2835
2023
Q4
$277K Hold
106,179
– – ﹤0.01% 2722
2023
Q3
$199K Sell
106,179
-75,800
-42% -$145K ﹤0.01% 2643
2023
Q2
$457K Sell
181,979
-333,959
-65% -$609K ﹤0.01% 2368
2023
Q1
$903K Buy
515,938
+229,738
+80% +$627K ﹤0.01% 1928
2022
Q4
$1.22M Buy
+286,200
New +$521K ﹤0.01% 1601

Other funds holding SMMT

Two Sigma Investments's SMMT Position: Q3 2026 in Review

Two Sigma Investments increased its Summit Therapeutics (SMMT) stake by 224% in Q3 2026, buying an estimated $23.4M and bringing the position to 2,259,925 shares worth $38.2M. The position accounts for 0.03% of the portfolio, ranked #672.

Two Sigma Investments first reported a position in SMMT in Q4 2022 and has held it in 11 quarters since. 296 funds tracked by Wall St. Rank hold SMMT as of Q3 2026.

  • Two Sigma Investments held 2,259,925 shares of Summit Therapeutics worth $38.2M as of Q3 2026.
  • Two Sigma Investments bought 1,563,211 Summit Therapeutics shares in Q3 2026, an estimated $23.4M.
  • Summit Therapeutics made up 0.03% of Two Sigma Investments's portfolio in Q3 2026, its #672 holding.
  • Two Sigma Investments first reported a position in Summit Therapeutics in Q4 2022 and has held it in 11 quarters since.
  • 296 funds tracked by Wall St. Rank held Summit Therapeutics as of Q3 2026.

Based on Two Sigma Investments's 13F filing for Q3 2026, filed 16 Nov 2026.